The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,831.00
Bid: 1,830.00
Ask: 1,832.00
Change: 12.00 (0.66%)
Spread: 2.00 (0.109%)
Open: 1,818.00
High: 1,838.00
Low: 1,815.00
Prev. Close: 1,819.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

13 Apr 2021 11:35

RNS Number : 3133V
Hikma Pharmaceuticals Plc
13 April 2021
 

Hikma Pharmaceuticals PLC

 

 

Block Listing Six Monthly Return

 

Date: 13 April 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

 

Period of return

From: 1 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

Block Listing Six Monthly Return

 

Date: 13 April 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 57,502 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 13 April 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("2009 MIP")

Period of return

From: 1 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

2009 MIP: 139,696 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2009 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2009 MIP: 3,514 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2009 MIP: 136,182 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 13 April 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("2018 MIP")

Period of return

From: 1 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

2018 MIP: 1,000,000 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2018 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2018 MIP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2018 MIP: 1,000,000 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 13 April 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From: 1 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

EIP: 512,424 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EIP: 1,000,000 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EIP: 272,457 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

EIP: 1,239,967 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRGPUUWCUPGGUW
Date   Source Headline
17th Apr 202410:42 amRNSDirector/PDMR Shareholding
15th Apr 20244:43 pmRNSHikma appoints new President of Generics business
11th Apr 202410:58 amRNSDirector/PDMR Shareholding
2nd Apr 20249:50 amRNSBlock listing Interim Review
22nd Mar 20249:21 amRNSAnnual Financial Report and Notice of AGM
13th Mar 20249:42 amRNSDirector/PDMR Shareholding
7th Mar 20241:52 pmRNSDirector/PDMR Shareholding
1st Mar 202410:17 amRNSTotal Voting Rights
22nd Feb 20247:00 amRNSFinal Results
5th Feb 20248:46 amRNSNotice of Results
1st Feb 20246:22 pmRNSAgreement in Principle for US Opioid Settlement
1st Feb 202412:08 pmRNSTotal Voting Rights
2nd Jan 20243:24 pmRNSTotal Voting Rights
29th Dec 20237:00 amRNSCompany Secretary Change
1st Dec 20237:00 amRNSTotal Voting Rights
2nd Nov 20237:00 amRNSTrading Statement
2nd Oct 202310:13 amRNSBlock listing Interim Review
2nd Oct 202310:04 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSTotal Voting Rights
31st Aug 20234:14 pmRNSDirector/PDMR Shareholding
11th Aug 20232:00 pmRNSDirector/PDMR Shareholding
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report
17th Jul 20239:11 amRNSNotice of Results
14th Jun 202310:03 amRNSHolding(s) in Company
8th Jun 202310:25 amRNSDirector/PDMR Shareholding
31st May 20233:20 pmRNSDirector/PDMR Shareholding
23rd May 20234:14 pmRNSHolding(s) in Company
17th May 20239:56 amRNSDirector/PDMR Shareholding
2nd May 202310:53 amRNSTotal Voting Rights
28th Apr 20233:25 pmRNSResult of AGM
28th Apr 20237:00 amRNSTrading Statement
24th Apr 20234:15 pmRNSDirector/PDMR Shareholding
12th Apr 20237:00 amRNSDirectorate Change
3rd Apr 20239:27 amRNSBlock listing Interim Review
3rd Apr 20239:19 amRNSTotal Voting Rights
16th Mar 202310:17 amRNSAnnual Financial Report and Notice of AGM
2nd Mar 20239:30 amRNSTotal Voting Rights
23rd Feb 20237:00 amRNSFinal Results
17th Feb 202310:20 amRNSHolding(s) in Company
7th Feb 20239:36 amRNSNotice of Results
1st Feb 202310:18 amRNSTotal Voting Rights
18th Jan 202310:16 amRNSDirector/PDMR Shareholding
18th Jan 20239:39 amRNSHolding(s) in Company
17th Jan 202311:58 amRNSHolding(s) in Company
10th Jan 20233:42 pmRNSAdditional Listing
10th Jan 20239:20 amRNSDirector/PDMR Shareholding
3rd Jan 20239:23 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSHikma launches sodium oxybate in the US
1st Dec 20229:24 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.